- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05441267
A Study of Cardiovascular Events iN Diabetes Plus (ASCEND PLUS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
ASCEND PLUS aims to assess the effects of the GLP1 receptor agonist, oral semaglutide, on major adverse cardiovascular events in people with type 2 diabetes who have not previously suffered a heart attack or stroke. The study will be conducted using novel, streamlined methodology. Participants will be identified from centrally held routinely collected NHS healthcare datasets and invited to join the trial. There will be no physical sites, and all interactions with participants will be conducted directly using innovative patient-centred web-based technology, supplemented by telephone, video call contact and mailed letters.
Study treatment will be mailed to participants. Information regarding serious adverse events and study outcomes relevant to patients with type 2 diabetes mellitus will be collected by regular linkage to UK National Health Service health records both during the scheduled treatment period and for the subsequent 20 years' long term follow-up after the scheduled treatment period.
The trial design includes an active run-in phase, prior to randomisation, during which participants will be asked to take 4-weeks of active 3mg oral semaglutide followed by 4 to 8-weeks of active 7mg oral semaglutide daily.
Participants who are randomised will be allocated to receive either 14mg oral semaglutide or matching placebo daily during the scheduled treatment period. There will be the opportunity to reduce the dose to 7mg or matching placebo if required.
The scheduled treatment period, during which participants are requested to take the study treatment and complete follow-up assessments, is anticipated to continue until the required number of participants has experienced a primary outcome following randomisation. This is expected to occur at a median of approximately 5 years after randomisation.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Oxford, United Kingdom
- Recruiting
- Clinical Trial Service Unit and Epidemiological Studies Unit
-
Contact:
- David Preiss
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults aged at least 55 years at the time of the Screening assessment
- Type 2 Diabetes Mellitus (based on self-reported medical history)
Exclusion criteria:
- Myocardial Infarction
- Stroke
- Current or planned treatment with a GLP-1 RA
- Previous hypersensitivity to or intolerance of GLP-1 RA therapy
- Severe hypoglycaemia within the last six months or during run-in
- Symptomatic hypoglycaemia within the last month
- Currently under consideration to commence insulin
- Severe heart failure (NYHA class 4)
- Current or planned renal replacement therapy
- Unwilling to complete regular follow-up assessments
- Ongoing treatment for cancer or diagnosis with cancer (excluding non-melanoma skin cancer) in the last 2 years
- Type 1 or other type of diabetes (e.g. MODY)
- History of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma
- Currently breastfeeding or pregnant, or planning a pregnancy
- Any serious illness which is likely to limit survival or active participation for at least 5 years
- Current participation in a clinical trial with an unlicensed investigational medicinal product used to treat diabetes
- For participants taking thyroxine, lack of agreement to arrange a thyroid function test in the next 3 months and agree to regular testing throughout the trial
- Non-adherence to run-in treatment (i.e. reports taking the run-in tablets 'Never' or 'Only occasionally')
- Their doctor does not wish them to be randomised
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo oral semaglutide
|
Active Comparator: Oral semaglutide
14mg daily (option to reduce to 7mg daily)
|
Oral semaglutide 14mg daily (option to reduce to 7mg daily)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to the first occurrence of a Major Adverse Cardiovascular Events (MACE+)
Time Frame: Scheduled treatment period (anticipated median follow-up period of 5-years)
|
MACE+ is an expanded composite, defined as:
|
Scheduled treatment period (anticipated median follow-up period of 5-years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to the first occurrence of a Major Adverse Cardiovascular Events (MACE)
Time Frame: Scheduled treatment period (anticipated median follow-up period of 5-years)
|
MACE is a composite, defined as:
|
Scheduled treatment period (anticipated median follow-up period of 5-years)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTSU_ASCEND-PLUS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
Clinical Trials on Semaglutide Oral Tablet
-
Asian Institute of Gastroenterology, IndiaRecruiting
-
University Medical Centre LjubljanaUniversity of PalermoRecruitingDiabetes Mellitus, Type 2 | AtherosclerosisSlovenia
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2United States
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SWithdrawn
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SEnrolling by invitation